Key facts
- Iantrek’s last known valuation is $95.0M (Aug 2025).
- It has raised $73.0M across 4 recorded rounds; the latest was Early Stage VC ($34.7M) in Aug 2025.
- Notable investors include FemHealth Ventures, Civilization Ventures, JSD Capital, Sectoral Asset Management, U.S. Venture Partners — 7 tracked in total.
- Iantrek has filed 4 Form Ds with the SEC since 2020, most recently Aug 2025 ($34.7M sold to 21 investors).
- Status: Privately Held (backing).
Free account
See the evidence behind this price
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Iantrek
Create free account
No card required
Funding rounds
4 roundsAbout Iantrek
Developer of a minimally invasive technology designed to offer ophthalmic medical devices. The company offers advanced micro-interventional surgical technologies, enabling doctors to help in eye surgery with smaller incisions and shorter recovery times.
- Sector
- Healthcare
- HQ
- White Plains, NY, United States
- Founded
- 2019
- Employees
- 49
- Website
- iantrekmed.com/
- Ownership
- Privately Held (backing)
PA Mark — not yet priced
Iantrek doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Iantrek shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on Iantrek in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.